As of snapshot 27745 under ledger-default@0.3.0. Counts by assessment state, descriptive only: no topic is scored.
1 Insufficient evidence8 Supported
| Claim | Type | Assessment |
|---|
| The study analyzed 2,243 children aged 3–23 months hospitalized with acute gastroenteritis, of whom 638 were ELISA-positive for rotavirus. | QUANTITATIVE | Supported |
| In the study’s Indian hospital-based analysis, three ROTASIIL doses had estimated adjusted effectiveness of 56% against moderate rotavirus gastroenteritis and 54% against severe rotavirus gastroenteritis among children aged 3–23 months. | QUANTITATIVE | Supported |
| In the study’s Indian hospital-based analysis, three ROTASIIL doses had estimated adjusted effectiveness of 88% against rotavirus-gastroenteritis hospitalization among children aged 3–5 months. | QUANTITATIVE | Supported |
| In the AMP trials, prophylactic VRC01 selected de novo HIV escape mutations in 8 of 26 treated participants but none of 21 placebo participants; several mutations caused cross-resistance, while N6 and 1–18 largely retained activity. | QUANTITATIVE | Insufficient evidence |
| In the phase 1 mRNA-1215 trial, antibody responses increased after the booster dose and remained elevated for at least one year. | QUANTITATIVE | Supported |
| In a phase 1, first-in-human trial of mRNA-1215 in 40 healthy adults, no serious adverse events occurred during the study. | QUANTITATIVE | Supported |
| An AI-guided Bayesian-optimization framework identified solid-state mRNA-lipid nanoparticle formulations that retained 100% bioactivity after more than two months at 37 °C, while inducing non-inferior antigen-specific responses in rodents and non-human primates versus fresh soluble vaccines. | QUANTITATIVE | Supported |
| Mice vaccinated with the heat-stored MIT RNA-LNP formulation showed equivalent immune responses to mice receiving a comparable Moderna-like RNA-LNP formulation. | COMPARATIVE | Supported |
| An MIT-developed lipid nanoparticle formulation kept RNA vaccine particles stable at room temperature for up to one year or at 37°C (98°F) for two months. | QUANTITATIVE | Supported |
Galedra